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INTRODUCTION
Vesicular traffic and transport is a
major part of cellular function. Most of
what we know from this field involves
intracellular traffic: the secretory pathway,
the endocytic pathway, the transcytotic
pathway, the recycling pathways, and the
protein sorting pathways, to name a few.
Over the last few years, however, a novel
form of vesicular traffic has been noted to
occur in cells of the hematopoetic system,
particularly cells of immune function.
What characterizes this phenomenon is a
newly studied form of intercellular traf-
ficking, in which the secreted product of
one cell is actually variable cargo on small
vesicular membranes termed "exosomes."
Exosomes were initially described as
50 to 90 nm vesicles released by reticulo-
cytes upon their final maturation into ery-
throcytes [1]. By electron microscopy, these
structures were seen to be found as vesicles
within multivesicular bodies (MVBs)b [2],
their biogenesis being thought to occur as
invaginations from the MVB limiting mem-
brane into its lumen [3]. Upon direct fusion
of the MVB limiting membrane with the
plasma membrane, these vesicles may be
released into the extracellular milieu. The
released vesicles are then termedexosomes.
Theprinciple function ofexosomes was ini-
tially thought to be the elimination ofplas-
ma membrane proteins no longer needed in
the mature erythrocyte, such as the transfer-
rin receptor [4].
The putative role of the exosome has
expanded recently, however, with the ini-
tial observation that similar vesicles are
secreted from Epstein-Barr Virus trans-
formed B lymphocytes [5]. A hallmark of
these B cell derived exosomes was that
they were enriched in MHC class II mole-
cules that could stimulate CD4+ T cell
clones in vitro [5]. Since then, several
papers published in the last few years have
begun to delineate the ever increasing
functions of exosomes in immune cell
function. This review will focus on some
of these recent observations.
a To whom all correspondence should be addressed: Khashayar Farsad, Department of
Cell Biology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520.
b Abbreviations: MVB, multivesicular bodies; APC, antigen presenting cells; CTL, cytotoxic
T cell; HSP, Heat shock proteins; AICD, activation-induced cell death; TNF, tumor necrosis




One very interesting potential role of
exosomes is in modulation of the immune
system to fight cancer. Dendritic cells,
which are one of the immune system's
most powerful professional antigen pre-
senting cells (APCs), have been noted to
be involved in cytotoxic T cell (CTL)
induction following various immunothera-
py protocols against tumor antigens [6].
Dendritic cells have been shown to pro-
duce exosomes bearing both MHC class I
and class II glycoproteins [7]. The exo-
somes isolated from in vitro cultured den-
dritic cells pulsed with acid eluted tumor
peptides were able to exert remarkable
antitumor effects in selected mice bearing
the tumors, similar to the effects of intact
dendritic cells [7]. The effect was achieved
with only a few micrograms of intrader-
mally injected material. These effects were
not seen with saline injection, nor with
exosomes from dendritic cells pulsed with
acid eluted peptides from the normal
spleen [7]. T cells isolated from the immu-
nized mice bore cytotoxic activity against
the tumor cells in vitro, showing that the
exosomes had induced a cytotoxic T cell
response in the host [7]. Moreover, nude
mice (with no functional immune system)
did not exhibit the antitumor effect ofexo-
some treatment, and neither did exosomes
bearing allogeneic MHC molecules, fur-
ther substantiating an immune mediated
antitumor response [7].
The finding ofMHC class I molecules
on exosomes was surprising, and may pos-
tulate a role in the immunomodulating
ability of these vesicles. One naive possi-
bility is that the exosome itself is present-
ing tumor peptide conjugated to MHC
class I to CTLs and initiating induction of
the cytotoxic response. This would pre-
sume the presence of the appropriate cos-
timulatory proteins on the exosomal mem-
brane. Accordingly, enrichment of CD86
(B7.2) has been found on exosomes [7]. In
effect, the exosomes could serve as long-
distance transducers of a specific immune
response. This would explain how poorly
immunogenic tumors, which have been
shown to cause downregulation ofcostim-
ulatory molecules from the APC cell sur-
face, could now be subject to immune
attack [7]. Exogenous MHC class I cou-
pled to tumor peptides could be providing
the necessary T cell inducing activity, for
example. One argument against the direct
induction ofCTLs by exosomes, however,
is the fact that in vitro, exosomes are not as
potent as dendritic cells themselves in T
cell induction [7]. T cell stimulation by
exosomes becomes much more efficient in
the presence of dendritic cells, making an
indirect mode of action more likely [7].
Recent work has begun to shed some
light as to the mechanism of action of the
exosomes in the antitumor response.
Biochemical characterization of the exo-
somes has revealed an interesting accumu-
lation of certain proteins both on the exo-
some membrane as well as within its
lumen [4, 8]. Specifically, hsc73, a heat
shock protein known to have antitumor
activity via an immune response, is highly
enriched potentially within the lumen of
the exosome [4].
Heat shock proteins (HSPs), like
hsc73, are stress-induced chaperonins
which bind to a large complement of
endogenous peptides [9]. HSPs isolated
from tumor cells can induce a potent anti-
tumor rejection response in tumor-bearing
mice [9]. Peptides associated with hsc73
are very efficiently loaded onto MHC class
I and II molecules ofAPCs [9], and there
is electron microscopic evidence that
HSPs can undergo receptor-mediated
endocytosis within APCs [10], helping to
account for the highly efficient in vivo
antitumor effect with nanogram amounts
of these molecules [10]. Interestingly,Farsad: Exosomes 97
hsc73, in the absence of any peptide, has
been shown to produce macrophage-
induced T cell stimulation as well [11].
This implies thatHSPs may have immuno-
genic or adjuvant qualities by themselves,
and perhaps the presence of certain pep-
tides bound to the HSPs could help in the
specificity of a potent immune response.
Exosomal hsc73 may be involved in trans-
fer ofpeptides for loading onto MHC mol-
ecules, stimulation of a generalized
immune response, or in some other as yet
unexpected phenomenon. Thus, although
potentially very interesting, determining
the specific role for hsc73 in the immuno-
biology of the exosome requires ongoing
investigation.
Furthermore, MFG-E8, a soluble
membrane-associated integrin binding
protein, as well as several members of the
tetraspan integral membrane proteins
involved in cell-cell contact, were
enriched on exosomes [4, 12]. Interes-
tingly, macrophages and immature den-
dritic cells express integrins that bind
MFG-E8, raising the possibility that the
exosomes may be targeted to these cells
[4]. This may also explain some ofthe evi-
dence implicating exosomes in indirect T
cell stimulation, as well as how exosomes
may serve as long-distance immunomodu-
lators. A certain dendritic cell, which is
bearing useful immunogenic peptides on
its MHC glycoproteins could now, via its
exosomes, endow several other antigen-
presenting cells with the given peptide in
the context of the appropriate MHC/cos-
timulatory/cell adhesion molecules. This
could increase the efficiency of the
immune response and is one explanation
for how small amounts ofexosomal mate-
rial are able to induce a potent antitumor
response in mice [7].
Of note, it was found that immature
dendritic cells, rather than mature dendrit-
ic cells found in secondary lymphoid tis-
sue, are the ones selectively producing
exosomes [4]. That these immature den-
dritic cells are found in peripheral tissues
argues that exosomes may be more
involved in sensitization of other dendritic
cells ratherthan directTcell activation [4].
This is also supported by the data dis-
cussed earlier, where exosomes in vitro
were relatively poor at T cell stimulation
unless dendritic cells were also present
[7]. Recently, the source of MHC class II
molecules on the surface offollicular den-
dritic cells has been shown to be ofexoso-
mal origin, rather than having been
expressed by the follicular dendritic cell
itselfand presented atthe cell surface [13].
Thus, follicular dendritic cells may be the
in vivo target ofexosomes, providing these
cells with MHC class II molecules that
may then be exploited in the immune
response [13]. Therefore, whether by indi-
rect priming ofAPCs with antigen-loaded
MHC I/II, direct CTL induction via anti-
gen loaded MHC class I, immunostimula-
tion and antigen loading by hsc73, or some
other undiscovered mechanism, exosomes
are potentially exciting new immunomod-
ulating factors that may be exploited in
novel antitumor therapeutics.
Interestingly, a recent report has
shown that tumor cells themselves may be
an important source of exosomes [14].
Exsosomal vesicles containing MHC mol-
ecules and tumor-derived antigens were
noted to be present in several different
mouse and human tumor cells [14].
Although these exosomes carried MHC
class I molecules, they were unable to
induce a cytotoxic T cell response in vitro;
however, they were able to induce a potent
T cell response when loaded onto human
dendritic cells [14]. Furthermore, the
tumor antigens present on the exosomes
were able to be transferred to the dendritic
cells and subsequently to generate a CD
4+-mediated cross-response as well [14].
Therefore, it appears as though tumor-
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tant source of tumor antigens that may
trigger a protective immune mediated anti-
tumor response. Moreover, the tumor anti-
gens present on these exosomes seemed to
be shared by several different tumor cell
types, raising the exciting possibility that
such exosomal antigens may be used for
cross vaccination against many different
tumor types [14].
EXOSOMES IN APOPTOSIS
Another potentially very interesting
role of immune cell exosomes is in induc-
tion of apoptosis. After a cellular immune
response, most of the activated T cells are
destroyed by activation-induced cell death
(AICD) to protect against damaging
autoimmune effects [15]. AICD ofmany T
cell lines is potentiated by FasL and
APO2L, two membrane-bound proteins
that are members of the tumor necrosis
factor (TNF) superfamily [15]. Upon bind-
ing to their respective receptors, these
transmembrane ligands induce apoptosis
in the appropriate receptor-bearing cells,
which frequently occurs as an autocrine or
paracrine response [15].
Previously, it has been shown that
supernatants from activated Jurkat cell
cultures or FasL transfected COS cells
have apoptotic activity against Fas
expressing cells [16, 17]. This activity was
found to be attributed to a soluble form of
FasL, formed by Zn2+-dependent metallo-
proteinases, but with much lower toxicity
than the nonproteolyzed molecule [15].
Afterward, it was shown that intact FasL
and APO2L released into culture super-
natant were associated with a particulate
fraction, and that the release was mediated
by stimulation of the T cells [15]. Release
of the toxic molecules was inhibited by
cytochalasin B, an inhibitor of actin
cytoskeletal reorganization necessary for
microvesicle generation in certain systems
[15]. Furthermore, the stimulation depen-
dent presence of 100 to 200 nm microvesi-
cles in the culture supematants was con-
firmed by electron microscopy [15]. The
microvesicle associated intact FasL was a
much more potent toxic agent than the sol-
uble form, indicating that the intact mole-
cule is the functional apoptotic inducer
[15]. Indeed, other work has correlated the
presence of soluble FasL with downregu-
lation of apoptosis [18].
What is the benefit of microvesicle
associated apoptotic signals? One clear
benefit is preservation of the membrane
bound form of the ligand, which has the
greater activity. Another is the potentially
greater surface area for ligand expression
compared with the plasma membrane [15].
Moreover, for reasons that are not entirely
clear, FasL and APOL associated with
microvesicles have a much higher cross-
linking efficiency when compared with the
plasma membrane associated molecules
[15]. In addition, microvesicles may poten-
tiate paracrine/autocrine responses by
incurring less mobility to the molecules
compared with their soluble forms, thereby
achieving high local concentrations [15].
A potentially intriguing possibility, by
analogy to the dendritic cell-derived exo-
somes, would be the specific targeting of
apoptotic transducers and receptors, via
cell-cell contact molecules, to particular
subsets ofcells. This could serve as a new
modulator for toxic immunomodulation.
In light ofthis, some tumor cell lines have
been shown to constitutively secrete Fas
and FasL on microvesicles [19]. It is
tempting to speculate that this could serve
either as a tumor specific self destruct
mechanism, or more ominously, as an
immunosuppressing activity. Future work
in the field should help further elucidate
the role of exosomes in apoptosis.
EXOSOMES ANDTOLERANCE
Another role for exosomes that has
emerged recently is in T cell-mediated
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that T cell expression of MHC class II
molecules may play an important role in
maintaining tolerance to peripheral self
antigens [20]. T cells can express MHC
class II molecules by two known methods:
The first is expression of endogenously
synthesized molecules, seen in blastogenic
T cells, and the second is through acquisi-
tion of exogenous molecules from profes-
sionalAPCs [20]. This exogenous acquisi-
tion is thought to occur through specifical-
ly targeted exosomes, via an antigen-spe-
cific interaction [20]. Moreover, once
acquired, these T cells can now confer the
same antigen/MHC class II complex to
other responder cells, providing evidence
for an active intercellular exchange ofanti-
gen/MHC class II among APCs and anti-
gen-specific T cells via exosomes [20].
T cells expressing MHC class II mol-
ecules, known as T-APCs, pulsed with
antigenic peptides have been shown to be
able to transfer these antigen bound MHC
molecules to activated responder T cells in
a T cell receptor-dependent fashion [20].
Three observations support the fact that
responder cells have acquired intact anti-
gen/MHC from a donor cell. The first is
that the acquisition was not blocked by
cyclohexamide, a potent inhibitor of pro-
tein synthesis [20]. Second, mitogenic
stimulation of the T cells, which is not
dependent on T cell receptor activation,
endowed those cells with the ability to
express allogeneic MHC molecules pre-
sent on respective APCs [20]. And finally,
lipophilic dye from APCs was able to be
transferred to activated responder T cells
coincident with the surface expression of
either syngeneic or allogeneic MHC mole-
cules, suggesting exosomal transfer [20].
What utility would this exosomal
transfer of antigen/MHC class II from a T
cell APC to a responder T cell serve? As
stated earlier, expression of MHC class II
on the surface ofT cells may be important
in mediating peripheral tolerance to self
antigens [20]. Positive selection within the
thymus enriches forT cells, which are able
to weakly bind self antigen/MHC [20].
This partial agonist activity has been
shown to correlate with acquisition of
MHC class II proteins on the T cell sur-
face, and the long-term expression ofthese
proteins is also dependent on this weak
interaction [20]. It is thought that T cells
bearing self antigens coupled to MHC
class II glycoproteins are involved in
maintaining tolerance to self antigens by
interacting with T cells through high-affin-
ity T cell receptors, but in the absence of
costimulatory molecules necessary for
generating an immune response [20].
Indeed, antigen presentation by T-APCs
has been shown to induce apoptosis or
anergy in responder cells [21].
Thus, whether a T cell generates an
immune response or becomes anergic
depends on a highly specific interaction
between the T cell receptor and the anti-
gen/MHC complex, as well as the pres-
ence or absence, respectively, of costimu-
latory molecules [20]. Exosomal transfer
of self antigen/MHC complex to other
potentially reactive T cells could help in
the maintenance of peripheral self-toler-
ance by rendering these cells now anergic,
and by propagation ofthe tolerogenic phe-
notype through generation ofadditional T-
APCs [20]. This was shown through injec-
tion of T-APCs pulsed with myelin basic
protein (MBP) into mice with experimen-
tal autoimmune encephalomyelitis (EAE),
an autoimmune demyelinating disease
with MBPreactive T cells. In treated mice,
the severity ofthe disease was significant-
ly diminished and corresponded with the
rapid acquisition of MHC class II expres-
sion on the surface ofreactive clones [20].
It would be interesting to see whether
these responder T cells with the newly
acquired antigen/MHC class II surface
expression could propagate the disease-
moderating activity to other syngeneic ani-
mals. Exosomal transfer of such tolero-
genic activity could potentially provide100 Farsad: Exosomes
very useful and efficient therapeutics
against autoimmune diseases and could
revolutionize transplant immunomodula-
tion. Further studies should continue to
elucidate the function of exosomes in
maintenance of self-tolerance.
PERSPECTIVE
In this review, the exciting relatively
recent discoveries of the role of exosomes
in immune function have been explored.
More and more, it is becoming clear that,
rather than being an epiphenomenon, exo-
somes are playing a fundamental role in
immunobiology. Furthermore, exosomes
have shown a diversity that poises them as
an interesting organelle to study from a
variety of standpoints. Depending on what
proteins constitute the exosomes, they
may have cytotoxic effects, immunomodu-
lating effects, apoptotic activity, and
tolerogenic activity.
These remarkable attributes have a lot
ofpotential for pharmacotherapeutic roles.
Moreover, the fact that they are small,
potent, and non-living makes them highly
attractive bioactive molecules on which to
focus therapeutics. Theoretically, if the
many constitutive features of exosomes
could be identified, then one could envi-
sion creating them in vitro for potential
manipulative purposes.
Thus, exosomes have begun to rede-
fine and expand the role of immune cell
function, particularly with respect to the
fundamental principles of antigen presen-
tation. Recent identification of exosomes
in intestinal epithelial cells and in mast
cells involved in B and T cell stimulation
is a harbinger of other as yet unidentified
sources of these organelles involved in
modulating the immune response [22, 23].
Exosome biology is only at its inchoate
stages, and future studies will hopefully
continue to provide more information on
the many functions of these versatile
organelles in immunology.
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